Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

 

Zwaan group

My research program includes translational research projects in pediatric oncology, with a special focus on experimental therapeutics/early drug development, and acute myeloid leukemias / Down syndrome related leukemias. I am also heading the Trial and Data Center at the Princess Máxima Center.

PI: Prof.dr. Michel Zwaan
Phone +31 88 97 25 206

 Laboratory research

The research program on myeloid leukemias is done in close collaboration with PIs in the Máxima Research Insititute, including the Stam group, the Van Boxtel group and the Heidenreich group. The program focuses on identifying determinants of clinical outcome to improve risk-group stratification, and to identify novel options for targeted treatment. Close collaboration exists with Dr. Tanja Gruber from St Jude Children’s research hospital (Memphis, USA), Dr Soheil Meshinchi from the Children’s Oncology Group (Seattle, USA), and Prof. Dirk Reinhardt from the BFM Group (Essen, Germany). Down ALL projects are performed in close collaboration with the Den Boer group.

PhD-student

In collaboration with

Project

Sanne Noort

Tanja Gruber (St Jude), Ronald Stam

Characterizing the mutational landscape in pediatric AML without known causative genetic aberration

Priscilla Wander

Ronald Stam

The role of NFkB in MLL-rearranged infant ALL

Naomi Michels

Monique den Boer

Molecular aberrations in pediatric Down Syndrome Acute Lymphoblastic Leukemia

Miriam Guillen-Navarro

Ronald Stam

Unraveling the role of alternative splicing in high-risk pediatric leukemia subtypes

Fabienne Adriaanse

Tanja Gruber (St Jude), Ronald Stam

Mechanisms of HOX mediated Leukemogenesis in Acute Myeloid Leukemia (AML)

Eline Bertrums

Ruben van Boxtel, Bianca Goemans, Marry Van den Heuvel-Eibrink

 

Romy van Weelderen

Gert-Jan Kaspers, Bianca Goemans

Clinical aspects of pediatric AML   

Eline Zijtregtop

Auke Beishuizen

Identification of biomarkers and novel therapeutic targets in pediatric Hodgkin lymphoma




Clinical Research

The early clinical trial program includes clinical studies of promising novel agents for children with cancer, and in addition focuses on therapeutic drug monitoring, bioequivalence studies of pediatric-friendly formulations, and age-dependent pharmacokinetics/dynamics.

Dr. Erica Brivio is appointed as fellow in pediatric drug development at the Trial and data center. Each of the units has a dedicated pediatric oncologist with a focus on early clinical trials:

 

  Fellow in pediatric drug development:          

  • Erica Brivio (Bosutinib and Inotuzumab Ozogamicin studies)
  • Lenneke Schrier (Neuroblastoma phase 1B basket trial)

    Hematological malignancies Unit
  • Inge van der Sluis
  • Britta Vormoor
  • Auke Beishuizen (lymphoma)
  • Caroline Lindemans (SCT)

    Solid tumor Unit
     
  • Natasha van Eijkelenburg
  • Miranda Dierselhuis (fellow pediatric oncology)

    Brain tumor Unit
  • Jasper van der Lugt
  • Dannis van Vuurden (pontine glioma)

    PhD students:


    Sebastiaan Sassen

    Ron Mathôt (AMC)

    Towards evidence-based use of ciprofloxacin prophylaxis and glucocorticoids for children with cancer

    Natasha van Eijkelenburg

     

    Drug development studies in pediatric oncology

    Laura Nijstad

    Alwin Huitema (NKI and UMCU)

    Pharmacokinetics and pharmacodynamics of antineoplastic agents in pediatric patients

    Erica Brivio

     

    Early clinical trials in children with leukemia


     




Zwaan group